favorites

Ozempic CEO’s exit from Novo started with Teams call surprise

“I think that’s part of the game, so to say. It’s not for me to judge the criteria," Lars Fruergaard Jorgensen said.

Naomi Kresge

Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.

Patients on semaglutide were less than half as likely to overdose as those on insulin.

Positive results in the early stages of Roche's weight-loss pill development had given investors hope it could quickly catch up with rivals Novo...

Positive results in the earliest stages of development have driven about $93 billion in market value gains this year for obesity-drug makers.